A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice

OBJECTIVE To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent allo- and autoimmune activation using a stringent model of islet transplantation and diabetes reversal. RESEARCH DESIGN AND METHODS Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig. RESULTS BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P < 0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100% diabetes reversal in newly hyperglycemic NOD mice and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice). CONCLUSIONS The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.

• Publication year

  2010

• Venue

  Diabetes

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2337/db09-1264PMID 20805386PMCID 2927948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice

  2009cited by this paper
• Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients

  2009cited by this paper
• Rabbit Polyclonal Mouse Antithymocyte Globulin Administration Alters Dendritic Cell Profile and Function in NOD Mice to Suppress Diabetogenic Responses 1

  2009cited by this paper
• Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice.

  2008cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells.

  2008cited by this paper
• Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation

  2008cited by this paper
• Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes

  2008cited by this paper
• Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes

  2008cited by this paper
• The Clinical Impact of Islet Transplantation

  2008cited by this paper
• FOXP3 Induced by CD28/B7 Interaction Regulates CD25 and Anergic Phenotype in Human CD4+CD25− T Lymphocytes1

  2008cited by this paper
• Characterization of Donor Dendritic Cells and Enhancement of Dendritic Cell Efflux With cc-Chemokine Ligand 21

  2007cited by this paper
• IL-15 Is Required for Sustained Lymphopenia-Driven Proliferation and Accumulation of CD8 T Cells1

  2007cited by this paper
• Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

  2006cited by this paper
• Rabbit antithymocyte globulin versus basiliximab in renal transplantation.

  2006cited by this paper
• International trial of the Edmonton protocol for islet transplantation.

  2006cited by this paper
• Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

  2006cited by this paper
• A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells.

  2006cited by this paper
• Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

  2005cited by this paper
• A comprehensive review of interventions in the NOD mouse and implications for translation.

  2005cited by this paper
• Individual Nonobese Diabetic Mice Exhibit Unique Patterns of CD8+ T Cell Reactivity to Three Islet Antigens, Including the Newly Identified Widely Expressed Dystrophia Myotonica Kinase1

  2004cited by this paper
• ISLET TRANSPLANTATION : ADVANCES AND IMMUNOLOGICAL CHALLENGES

  2004cited by this paper
• Cutting Edge: IL-7-Dependent Homeostatic Proliferation of CD8+ T Cells in Neonatal Mice Allows the Generation of Long-Lived Natural Memory T Cells 1

  2004cited by this paper
• Homeostatic proliferation is a barrier to transplantation tolerance

  2004cited by this paper
• Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells 1

  2003cited by this paper
• Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154.

  2003cited by this paper
• The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• CTLA4Ig-induced linked regulation of allogeneic T cell responses.

  2001cited by this paper
• Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.

  2001cited by this paper
• CTLA4Ig-Induced Linked Regulation of Allogeneic T Cell Responses1

  2001cited by this paper
• CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.

  1997cited by this paper
• CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301]

  1996cited by this paper
• Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response.

  1995cited by this paper
• Heart transplantation in congenic strains of mice.

  1973cited by this paper

• Best practices in islet transplantation in mice.

  2025cites this paper
• Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review

  2025cites this paper
• Is the NOD mouse a good model for type 1 diabetes?

  2025cites this paper
• Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapy.

  2025cites this paper
• Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes

  2023cites this paper
• Pharmacologically Enhanced Regulatory Hematopoietic Stem Cells Revert Experimental Autoimmune Diabetes and Mitigate Other Autoimmune Disorders

  2022cites this paper
• Acceptance of Murine Islet Allografts Without Immunosuppression in the Inguinal Subcutaneous White Adipose Tissue Pretreated with bFGF.

  2022cites this paper
• Suppression of Fibrotic Reactions of Chitosan-Alginate Microcapsules Containing Porcine Islets by Dexamethasone Surface Coating

  2021cites this paper
• Novel idebenone analogs block Shc's access to insulin receptor to improve insulin sensitivity.

  2020cites this paper
• Engineering immunomodulatory biomaterials for type 1 diabetes

  2019cites this paper
• Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model

  2019cites this paper
• Simultaneous Recognition of Allogeneic MHC and Cognate Autoantigen by Autoreactive T Cells in Transplant Rejection

  2018cites this paper
• Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition

  2018cites this paper
• Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research

  2018cites this paper
• PI 3 K γ Deficient NOD-Mice Are Protected from Diabetes by Restoring the Balance of Regulatory to Effector-T-Cells

  2017cites this paper
• MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset

  2017cites this paper
• Immunotherapy for type 1 diabetes

  2017cites this paper
• Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio

  2017cites this paper
• Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer

  2017cites this paper
• PI3Kγ Deficient NOD-Mice Are Protected from Diabetes by Restoring the Balance of Regulatory to Effector-T-Cells

  2017cites this paper
• PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes

  2017cites this paper
• Antifibrotic effect of rapamycin containing polyethylene glycol‐coated alginate microcapsule in islet xenotransplantation

  2017cites this paper
• Bioengineering the Endocrine Pancreas: Intraomental Islet Transplantation Within a Biologic Resorbable Scaffold

  2016cites this paper
• Lung-Derived Microscaffolds Facilitate Diabetes Reversal after Mouse and Human Intraperitoneal Islet Transplantation

  2016cites this paper
• miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of Children with Newly Diagnosed Type 1 Diabetes

  2016cites this paper
• Biopatterned CTLA4/Fc Matrices Facilitate Local Immunomodulation, Engraftment, and Glucose Homeostasis After Pancreatic Islet Transplantation

  2016cites this paper
• Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production

  2016cites this paper
• Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8+T Effector Memory Subset

  2015cites this paper
• THERAPY OF ENDOCRINE DISEASE: Islet transplantation for type 1 diabetes: so close and yet so far away.

  2015cites this paper
• Modern clinical management helps reducing the impact of type 1 diabetes in children.

  2015cites this paper
• Induction of tolerance and prolongation of islet allograft survival by syngeneic hematopoietic stem cell transplantation in mice.

  2015cites this paper
• Type 1 diabetes and T regulatory cells.

  2015cites this paper
• Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site

  2015cites this paper
• Novel immunological strategies for islet transplantation.

  2015cites this paper
• TIM4 Regulates the Anti-Islet Th2 Alloimmune Response

  2015cites this paper
• The rise, fall, and resurgence of immunotherapy in type 1 diabetes.

  2015cites this paper
• Immunogenicity of β-cells for autologous transplantation in type 1 diabetes.

  2015cites this paper
• Adoptive T Regulatory Cell Therapy for Tolerance Induction

  2015cites this paper
• odern clinical management helps reducing the impact of type 1 iabetes in children

  2015cites this paper
• ROLE OF ADIPOSE DERIVED MESENCHYMAL STEM CELLS IN IMPROVING STREPTOZOTOCIN-INDUCED DIABETES MELLITUS IN RATS

  2015cites this paper
• Novel therapies for T1D on the horizon.

  2015cites this paper
• Downregulation of lncRNA TUG1 Affects Apoptosis and Insulin Secretion in Mouse Pancreatic β Cells

  2015cites this paper
• The Combination of Anti‐NKG2D and CTLA‐4 Ig Therapy Prolongs Islet Allograft Survival in a Murine Model

  2014cites this paper
• Islet Remodeling in Female Mice with Spontaneous Autoimmune and Streptozotocin-Induced Diabetes

  2014cites this paper
• A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice.

  2014cites this paper
• Protective Effects of Combined Intervention with Adenovirus Vector Mediated IL-10 and IGF-1 Genes on Endogenous Islet β Cells in Nonobese Diabetes Mice with Onset of Type 1 Diabetes Mellitus

  2014influential citation
• Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice

  2014cites this paper
• Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.

  2014cites this paper
• PD-L1–Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice

  2014cites this paper
• The Gut Microbiota Modulates Glycaemic Control and Serum Metabolite Profiles in Non-Obese Diabetic Mice

  2014cites this paper
• Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

  2014cites this paper
• Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents

  2013cites this paper
• Pancreatic islet transplantation in type 1 diabetes mellitus: an update on recent developments.

  2013influential citation
• A Bispecific Protein Capable of Engaging CTLA-4 and MHCII Protects Non-Obese Diabetic Mice from Autoimmune Diabetes

  2013cites this paper
• Elevated Levels of Interferon-γ Production by Memory T Cells Do Not Promote Transplant Tolerance Resistance in Aged Recipients

  2013cites this paper
• Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model

  2013cites this paper
• Immunotherapeutic treatment of autoimmune diabetes.

  2013cites this paper
• Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7

  2013cites this paper
• Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection

  2013cites this paper
• Animal Models of Diabetes Mellitus for Islet Transplantation

  2012cites this paper
• The role of Thymoglobulin induction in kidney transplantation: an update

  2012cites this paper
• Inotuzumab Ozogamicin Murine Analog–Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses

  2011cites this paper
• IL-21 Is an Antitolerogenic Cytokine of the Late-Phase Alloimmune Response

  2011cites this paper
• Cryopreservation effects on the in vitro and in vivo function of a model pancreatic substitute

  2011cites this paper
• Current Status of Immunomodulatory and Cellular Therapies in Preclinical and Clinical Islet Transplantation

  2011cites this paper
• Immunoregulatory effect of anti-thymocyte globulin monotherapy on peripheral lymphoid tissues of non-obese diabetic mice.

  2011cites this paper
• Contribution of Different Mechanisms to Pancreatic Beta-cell Hyper-secretion in Non-obese Diabetic (NOD) Mice during Pre-diabetes*

  2011cites this paper
• A historical view from thirty eventful years of immunotherapy in autoimmune diabetes.

  2011cites this paper
• Long-term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2x7 Long-term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2x7 Running Title: Vergani Et Al.; Targeting P2x7r in Heart Transplantation

  year unknowncites this paper